Connect Biopharma Holdings (CNTB) Consolidated Net Income (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Consolidated Net Income for 3 consecutive years, with -$19.4 million the latest figure, recorded in Q1 2026.

• Quarterly Consolidated Net Income fell 88.84% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.6 million (down 275.46% YoY) and the FY2025 annual result came in at -$55.5 million, down 255.0% from the prior year.
• Consolidated Net Income eased to -$19.4 million in Q1 2026 per CNTB's latest filing, from -$15.1 million in the prior quarter.
• Over the last five years, Consolidated Net Income for CNTB reached as high as $14.8 million in Q2 2024 and fell as low as -$19.4 million in Q1 2026.
• A 3-year average of -$10.1 million and a median of -$12.9 million in 2024 frame the typical range for Consolidated Net Income.
• The largest YoY upside for Consolidated Net Income was 18.16% in 2025 against a maximum downside of 186.88% in 2025.
• Year by year, Consolidated Net Income stood at -$8.9 million in 2024, then plunged by 69.65% to -$15.1 million in 2025, then dropped by 28.39% to -$19.4 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$19.4 million, -$15.1 million, and -$17.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.